In China, For Global
An innovative and globally competitive
biopharmaceutical company with a whole-industry-chain layout.
In China, For Global
An innovative and globally competitive
biopharmaceutical company with a whole-industry-chain layout.
Original Innovation, Science Oriented
Globally-integrated R&D process
Technology system encompassing the entire lifecycle of antibodies
Innovation-driven Biopharma
China’s leading innovative biopharmaceutical company
Established in December, 2012
Therapeutic Area
Oncology
Toripalimab (PD-1), Tifcemalimab (BTLA)…
Autoimmune
Adalimumab (TNF-α), JS005 (IL-17A), UBP1213sc (BLyS)
Metabolic
Ongericimab (PCSK9), JS103 (Uricase), JS401 (ANGPTL3)…
Neurological
Infectious
Etesevimab (S protein), Deuremidevir Hydrobromide (RdRp)…
Therapeutic Area
Oncology
Autoimmune
Metabolic
Neurological
Infectious
Learn more
2012.12
Junshi Biosciences was established in Shanghai, the PRC.
2018.12
Toripalimab（TUOYI® , JS001）was granted marketing approval by the NMPA.
2023.10
Toripalimab（LOQTORZI™）was granted marketing approval by the FDA.
Learn more
News Center
Sep 7, 2025
君实生物宣布JS005（IL-17A单抗）治疗中重度斑块状银屑病的Ⅲ期临床研究达到共同主要研究终点和关键次要终点
>JS005在治疗中重度斑块状银屑病的一项多中心、随机、双盲、平行、安慰剂对照的关键注册性Ⅲ期临床研究中取得阳性结果
View details
Aug 8, 2025
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
>The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.
View details
May 27, 2025
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
>The NMPA has recently approved ongericimab's two sNDA, becoming China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients
View details
Apr 25, 2025
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.
View details
